Abstract:Radiotherapy (RT) and immunotherapy (IT) are the powerful tools for cancer treatment which act through the stimulation of immune response, and evidence suggest that combinatorial actions of these therapies may augment each other's beneficial effect through complex synergistic mechanisms. These molecular strategies are designed to target rapidly dividing cancer cells by either directly or indirectly inducing DNA damage. However, when cells detect DNA damage, they activate a range of signalling pathways known as the DNA damage response (DDR) to repair. Strategies are being developed to interfere with the DDR pathways in cancer cells to ensure their damage-induced degeneration. The stability of a cell's genetic material is largely dependent on the efficacy of DNA repair and therefore, an in-depth understanding of DNA damages and repair mechanism(s) in cancer cells is important to develop a promising therapeutic strategies for ensuring the efficacy of damage-induced tumor cell death. In recent years, a wide range of small molecule drugs have been developed which are currently being employed to combat the DNA repair deficiencies associated with tumor cells. Sequential or concurrent use of these two modalities significantly enhances the anti-tumor response, however with a concurrent probability of increased incidence of symptomatic adverse effects. With advent of newer IT agents, and administration of higher doses of radiation per fraction, such effects are more difficult to predict owing to the paucity of randomized trial data. It is well established that anti cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4), anti- Programmed cell death protein 1(PD-1), anti-Programmed cell death one ligand 1 (PD-L1) can be safely administered with RT and many studies have demonstrated survival benefit with such combination for patients with metastatic malignancy. However, the biology of radioimmunotherapy (RT/IT) is still an open area where research need to be focused to determine optimum dosage specially the interaction of the RT/IT pathways to determine optimum dosing schedule. In the current article we have summarised the possible intracellular immunological events that might be triggered when RT and IT modalities are combined with the DDR antagonists and highlighted present clinical practices, outcome, and toxicity profile of this novel treatment strategy.

Prospects for combining targeted and conventional cancer therapy with immunotherapy

Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions

Combined Targeted Therapy and Immunotherapy for Cancer Treatment

Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy

Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?

Rational combinations of immunotherapeutics that target discrete pathways

Next-generation combination approaches for immune checkpoint therapy

Emerging strategies in cancer therapy combining chemotherapy with immunotherapy.

Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System

Immuno-oncology Combinations: A Review of Clinical Experience and Future Prospects

Synergistic effects of radiotherapy and targeted immunotherapy in improving tumor treatment efficacy: a review

Combining immunotherapy and radiation therapy in gastrointestinal cancers: A review

Combination strategies to maximize the benefits of cancer immunotherapy

Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors

Clinically approved combination immunotherapy: Current status, limitations, and future perspective

Combining Radiation with Immunotherapy: The University of Pennsylvania Experience

Immunotherapy - Strategies for Expanding Its Role in the Treatment of All Major Tumor Sites

Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades

The next chapter in immunotherapy and radiation combination therapy – cancer-specific perspectives

Immune Checkpoint Inhibitor-Based Strategies For Synergistic Cancer Therapy

The future of cancer treatment: combining radiotherapy with immunotherapy